The Short Version
South Korea does have an approved human treatment for knee cartilage defects that is described in regulatory, clinical, and independent sources as a regenerative cell therapy. The strongest evidence is MFDS approval of CARTISTEM and supporting clinical literature. The main caveat is that approval is for specific knee cartilage defects, not all forms of knee cartilage loss, and regeneration is not guaranteed in every patient.